A Study to Evaluate Baricitinib in Adult Patients with Severe or Very Severe Alopecia Areata

Dermatology

Official Title

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe or Very Severe Alopecia Areata BRAVE-AA1

Purpose

The purpose of this study is to evaluate the efficacy of baricitinib.

Could this study be right for you?

  • Subject must self-identify as Black or African American 
  • Subject's current episode of alopecia areata must be more than 6 months and no longer than 8 years
  • Subject must not have any spontaneous improvement 
  • Subject must be in good general health with no history of tuberculosis, heart disease, cancer, HIV, hepatitis B or C, or blood clots 
  • Female subjects must not be pregnant, breastfeeding, or considering becoming pregnant for the duration of the study 

Age Range

18 years and up